Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report

RATIONALE: Although most of non-small cell lung cancer (NSCLC) patients with ROS1-fusions respond to crizotinb, acquired resistance eventually develop. The next-generations of ROS1 inhibitors have made some achievements, but the effects of immunotherapy have not been explored. PATIENT CONCERNS: A 44...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Tao, Xu, Rui, Yan, Bing, Li, Fang, Liu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314749/
https://www.ncbi.nlm.nih.gov/pubmed/30593165
http://dx.doi.org/10.1097/MD.0000000000013797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314749/
https://www.ncbi.nlm.nih.gov/pubmed/30593165
http://dx.doi.org/10.1097/MD.0000000000013797

Ejemplares similares